Home Endometrial cancer in a renal transplant recipient: A case report
Article Open Access

Endometrial cancer in a renal transplant recipient: A case report

  • Na Liu , Lei Yang , Yan Long and Guoqing Jiang EMAIL logo
Published/Copyright: October 1, 2020

Abstract

As the most effective treatment for end-stage renal diseases, renal transplantation can improve the quality of life of patients and prolong the survival time. However, during the prolonged survival time, malignancy has become one of the main causes of death of recipients, which vary geographically. Tumors in the digestive system and urothelial tumors have been highly reported in Asia. In general, the gynecological malignant tumors have been rarely reported, especially the endometrial carcinoma. Herein, a 63-year-old female renal transplant recipient diagnosed with endometrial carcinoma (15 years after transplantation) was reported. The patient had suffered irregular postmenopausal bleeding for a short time before hospitalization. She underwent abdominal hysterectomy, bilateral salpingo-oophorectomy, right pelvic lymphadenectomy, right para-aortic lymphadenectomy and omental excision. Postoperative pathology showed ovarian and pelvic lymph node metastasis and pathological stage IIIC. After six courses of chemotherapy with paclitaxel 270 mg + carboplatin 500 mg, the patient’s renal function was normal. During the third cycle of chemotherapy, the patient suffered a third-degree bone marrow suppression and returned to normal soon when treated with the recombinant human granulocyte stimulating factor. In conclusion, early screening of gynecologic tumors is important for female patients after renal transplantation, which has a positive significance for the prognosis improvement.

1 Introduction

As the most effective treatment for end-stage renal failure, renal transplantation can improve the survival of patients and their quality of life. However, with prolonged survival time and the application of immunosuppressive agents, malignancies might become one of the main causes of death for renal transplant recipients with functioning graft.

There have been reports concerning skin cancer and lymphoma in renal transplant recipients [1], and one study from our hospital has revealed that urothelial cancer is the predominant tumor in Chinese renal transplant recipients [2]. However, there are few reports about the gynecological malignancies except for cervical cancer in renal transplant recipients.

In the United States, endometrial cancer is the fourth most common invasive gynecologic cancer [3]. Among the renal transplant recipients, endometrial cancer is sporadic, and the standardized incidence ratio for uterine cancers has been reported to range from 0.9 to 2.1 per 1,00,000 females [4,5,6,7,8,9,10,11,12]. In this study, an endometrial cancer patient with renal allograft was reported, and cisplatin-based chemotherapy in renal transplant recipients was also explored. The importance of a close follow-up after renal transplant surgery was highlighted, including regular gynecologic screening for endometrial lesions.

2 Case report

A 63-year-old patient (gravida 2, and para1) was admitted to the Beijing Friendship Hospital for postmenopausal bleeding, with the diagnosis of uterus endometrial lesions. The patient had received left kidney transplantation without bilateral nephrectomy in 2002 because of the end-stage renal disease secondary to chronic glomerulonephritis. Then, she menopaused in 2004. At admission, during the 16 years following the renal transplantation, the patient had been on cyclosporine A (150 mg twice daily), prednisone (60 mg once daily), and mycophenolate mofetil (1,500 mg twice daily). During the perimenopause period, the patient was subjected to the ultrasound examination of uterus, and no abnormality had been detected.

The patient complained of vaginal bleeding for more than 10 days before the hospitalization. Clinical laboratory test results of tumor biomarkers showed that pre-operative CA125 was 332.5 U/mL and pre-operative CA199 was 111.14 U/mL. Transvaginal ultrasound revealed that the normal size and shape of uterus and the anteverted endometrium (8 mm anteriorly, 9 mm posteriorly) with fluid in cavity. The total endometrial thickness was 17 mm, with rich blood flow. Endometrial cancer was confirmed after the hysteroscopy and segmental curettage. Pelvic magnetic resonance imaging (MRI) indicated the possibility of the FIGO-stage IA endometrial carcinoma (Figure 1). The patient underwent abdominal hysterectomy, bilateral salpingo-oophorectomy, right pelvic lymphadenectomy, right para-aortic lymphadenectomy and omental excision. Pathology report confirmed the FIGO-stage IIIC endometrial adenocarcinoma with extrailiac lymph node metastasis (Figure 2). Both tumor biomarkers of CA125 and CA199 returned to normal after operation (less than 30 µ/mL).

Figure 1 Preoperative MRI image. The white arrow indicates the transplanted kidney. The black arrow indicates the FIGO-stage IA endometrial carcinoma.
Figure 1

Preoperative MRI image. The white arrow indicates the transplanted kidney. The black arrow indicates the FIGO-stage IA endometrial carcinoma.

Figure 2 Postoperative pathology images. (a) HE staining of the uterus after surgery showed that the tumor invaded more than half of the muscle layer, and some reached the serosa layer. Magnification: 100×. (b) Lymph node metastasis after the tumor surgery, shown by HE staining. Magnification: 100×.
Figure 2

Postoperative pathology images. (a) HE staining of the uterus after surgery showed that the tumor invaded more than half of the muscle layer, and some reached the serosa layer. Magnification: 100×. (b) Lymph node metastasis after the tumor surgery, shown by HE staining. Magnification: 100×.

The patient started the adjuvant treatment of carboplatin (500 mg) and paclitaxel (270 mg), starting from day 7 after surgery. At the first follow-up during the three cycles of chemotherapy, the patient complained of sciatic nerve pain that had been worsening in the past several weeks. Moreover, after the third cycle of chemotherapy, serious marrow suppression occurred, without liver or kidney injuries, which recovered soon after the application of G-CSF. The sixth cycle of chemotherapy was completed in July 2017. Moreover, she was subjected to immunosuppressive therapy during and after chemotherapy as before treatment. Thereafter, the patient was closely followed up in the outpatient clinic. The renal function indicator during surgery and chemotherapy showed that creatinine fluctuated at 60–92 µmol/L (within the normal range). The glomerular filtration rate was 116 mL/min before chemotherapy and 122 mL/min after chemotherapy. No recurrence was observed according to the computed tomography scanning at 28 months after surgery.

Ethical statement: This study was approved by Beijing Friendship Hospital, Capital Medical University. Written informed consent was obtained from this patient.

3 Discussion

Malignancies represent one of the main causes of death for renal transplant recipients with prolonged survival time, with other influencing factors such as the ages of donor and recipient and the responses of immunosuppressive therapy. Studies have suggested that malignant tumors would occur in about 20% of patients within 10 years after renal transplantation [13]. Malignancies after renal transplantation exhibited significant differences in different endemic and geographic regions. Skin cancer and lymphoma are most common in Europe (40%) and the USA (12–30%) [4], while digestive tract tumors are most common in Japan (57%) and South Korea (40%) [14,15]. Moreover, cervical and vulvovaginal tumors in renal transplant recipients have been reported approximately five times more common in the US population [16]. Bobrowska et al. [17] reported that endometrial hyperplasia was detected in 31 cases (69%) of the renal allograft recipients and that endometrial cancer was only detected in one case (2%) of the renal allograft recipients. Although women receiving renal transplant seem to have extremely high risk of endometrial hyperplasia, there are rare reports of endometrial cancer in the renal transplant recipients. There is no previous article focusing on the treatment of endometrial cancer in the renal transplant recipients. In this paper, we first discussed the treatment, especially chemotherapy, immunosuppressive program of the endometrial cancer in the renal transplant recipients.

In this study, the renal transplant patient had postmenopausal vaginal bleeding for more than 10 days. Postoperative pathology results confirmed stage IIIC cancer. The main risk factors for endometrial cancers are related to excessive estrogen, nulliparity, diabetes mellitus, and tamoxifen application. Estrogen stimulation has been believed to be the main etiologic factor for endometrial cancer development [18]. Cancers of renal transplant recipients are always characterized by enhanced aggressiveness, as compared with patients receiving no transplantation. Effects of immunosuppressive drugs related to aggressiveness should be taken into account.

There would be alterations in the anatomic structure of the pelvis after the transplantation of a recipient kidney, such as the adhesions of the kidney with surrounding tissues, and connection of the renal arteriovenous with iliac vessels. It is difficult to perform ipsilateral pelvic lymphadenectomy without inducing any injuries for the donor kidney. In the case reported herein, the transplanted kidney was firmly adherent to the iliac vessels, which totally obliterated the obturator fossa. Therefore, no pelvic lymphadenectomy was performed on the left side because of the risks concerning renal function loss and fatal vascular injury. For patients with advanced tumors, abdominal aortic lymphadenectomy would be necessary. Although the para-aortic tissue may adhere to the transplanted kidney, it is still possible to remove the adhesive para-aortic lymph nodes. The patient reported herein was associated with advanced endometrial cancer and underwent a successful para-aortic lymphadenectomy. It was noteworthy that complete hemostasis in the surgical area played a key role because of the serious adhesion.

Renal transplant recipients with gynecological malignant tumors have been rarely reported. Therefore, the experience of chemotherapy treatment could only be learned from other malignant tumors. The combination of chemotherapeutic agents and immunosuppressive agents often leads to severe bone marrow suppression. Taxanes exert antineoplastic activity by stabilizing cell microtubules, which thus inhibits cellular mitosis and lead to cell cycle arrest. Common toxic effects mainly include myelosuppression, nausea and vomiting, and hypersensitivity reactions. Given this extensive liver metabolism, dose reductions are necessary with hepatic dysfunction. Paclitaxel can be safely used in patients, even in those with renal insufficiencies [19]. The platinum agents would induce the impairment of DNA replication and transcription, therefore resulting in apoptosis. The major toxic effects of cisplatin and carboplatin include myelosuppression, nephrotoxicity, neurotoxicity and ototoxicity [20]. Given the high propensity of nephrotoxicity, cisplatin is contraindicated in preexisting renal impairment. Dose reductions are thought to be necessary for renal function in some cases [2]. In the case reported herein, the patient was treated with a paclitaxel plus carboplatin regimen, every 4 weeks, for a total of six courses (paclitaxel 175 mg/m2, and carboplatin 300 mg/m2; all of them were regular doses). Severe myelosuppression occurred after the third course, which recovered soon after the application of the granulocyte-stimulating factor, with normal renal function. Of course, chemotherapy for the transplant recipients still needs to be further explored in future.

Specific recommendations for modifications of immunosuppression following malignancy diagnosis in transplant recipients have not been well established. The most common approach is the reduction or even elimination of maintaining immunosuppression [21]. Without modifications of immunosuppression drug dose, the patient in this study had normal renal function during the treatment.

In order to avoid pelvic graft injury, no radiotherapy was conducted. There are seldom reports of postoperative radiotherapy for malignancies in renal transplant recipients. However, Nicola et al. [22] have reported a case of the application of intensity-modulated radiation therapy (IMRT) for a 60-year-old man with T3bN1M0 prostate adenocarcinoma. Their results have shown that complex dose distributions achieved with IMRT enable the safe delivery of radical dose-escalated radiation therapy to the pelvic lymph nodes in the presence of a pelvic-transplanted kidney. Renal transplant should not be considered as a contraindication to pelvic radiotherapy.

In summary, gynecologic tumors after kidney transplantation have been rarely reported. Radical excision of the lesion should be considered based on the evaluation of the graft function. Moreover, radiotherapy and chemotherapy are feasible. Early screening for gynecological tumors after kidney transplantation is particularly important, which can significantly improve the disease prognosis.


Contributed equally.

tel: +86-13-91-172-1766

Acknowledgments

This work was supported by Beijing Key Gynecology Special Fund.

  1. Conflict of interest: Authors state no conflict of interest.

References

[1] Galve ML, Cuervas-Mons V, Figueras J, Herrero I, Mata M, Clemente G, et al. Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc. 1999;31(1–2):1275–7. 10.1016/s0041-1345(98)01994-0.Search in Google Scholar PubMed

[2] Zhang A, Shang D, Zhang J, Zhang L, Shi R, Fu F, et al. A retrospective review of patients with urothelial cancer in 3,370 recipients after renal transplantation: a single-center experience. World J Urol. 2015;33(5):713–7. 10.1007/s00345-014-1412-4.Search in Google Scholar PubMed

[3] Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67(1):7–30. 10.3322/caac.21387.Search in Google Scholar PubMed

[4] Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901. 10.1001/jama.2011.1592.Search in Google Scholar PubMed PubMed Central

[5] Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67. 10.1016/S0140-6736(07)61050-2.Search in Google Scholar PubMed

[6] Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA. HPV-related cancers after solid organ transplantation in the United States. Am J Transplant. 2013;13(12):3202–9. 10.1111/ajt.12472.Search in Google Scholar PubMed PubMed Central

[7] Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–7. 10.1038/sj.bjc.6601219.Search in Google Scholar PubMed PubMed Central

[8] Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31. 10.1001/jama.296.23.2823.Search in Google Scholar PubMed

[9] Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941–8. 10.1111/j.1600-6143.2007.01736.x.Search in Google Scholar PubMed

[10] Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43(14):2117–23. 10.1016/j.ejca.2007.07.015.Search in Google Scholar PubMed

[11] Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13. 10.1111/j.1600-6143.2004.00450.x.Search in Google Scholar PubMed

[12] Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010;10(8):1889–96. 10.1111/j.1600-6143.2010.03181.x.Search in Google Scholar PubMed

[13] Sprangers B, Nair V, Launay-Vacher V, Riella LV, Jhaveri KD. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J. 2018;11(3):315–29. 10.1093/ckj/sfx12.:3.Search in Google Scholar

[14] Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int. 2004;54(9):649–58. 10.1111/j.1440-1827.2004.01676.x.Search in Google Scholar PubMed

[15] Heo J, Noh OK, Oh YT, Chun M, Kim L. Cancer risk after renal transplantation in South Korea: a nationwide population-based study. BMC Nephrol. 2018;6;19(1):311. 10.1186/s12882-018-1110-3.Search in Google Scholar PubMed PubMed Central

[16] Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13. 10.1111/j.1600-6143.2004.00450.x.Search in Google Scholar

[17] Bobrowska K, Kamiński P, Cyganek A, Pietrzak B, Jabiry-Zieniewicz Z, Durlik M, et al. High rate of endometrial hyperplasia in renal transplanted women. Transplant Proc. 2006;38(1):177–9. 10.1016/j.transproceed.2005.12.007.Search in Google Scholar PubMed

[18] Phipps AI, Doherty JA, Voigt LF, Hill DA, Beresford SA, Rossing MA, et al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endo-metrial cancer. Cancer Causes Control. 2011;22(12):1639–46. 10.1007/s10552-011-9840-6.Search in Google Scholar PubMed PubMed Central

[19] Lüftner D, Flath B, Akrivakis C, Prinz B, Mergenthaler HG, Wernecke KD, et al. Feasibility of dose-intensified paclitaxel after chemotherapy-induced renal insufficiency in a patient with renal transplantation. Eur J Cancer. 1999;35(2):325. 10.1016/s0959-8049(98)00265-2.Search in Google Scholar PubMed

[20] Krisl JC, Doan VP. Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients. Am J Transplant. 2017;17(8):1974–91. 10.1111/ajt.14238.Search in Google Scholar PubMed

[21] Dierickx D, Tousseyn T, de Wolf-Peeters C, Pirenne J, Verhoef G. Management of post-transplant lymphoproliferative disorders following solid organ transplant: an update. Leuk Lymphoma. 2011;52:950. 10.3109/10428194.2011.557453.Search in Google Scholar PubMed

[22] Nicola R, Richard C, Michelle L, Carole M, Neill D. Intensity modulated radiation therapy allows prostate and dose-escalated pelvic radical radiation therapy after renal transplantation. Pract Radiat Oncol. 2015 5(3):e207–13. 10.1016/j.prro.2014.08.016.Search in Google Scholar PubMed

Received: 2020-03-12
Revised: 2020-07-19
Accepted: 2020-08-13
Published Online: 2020-10-01

© 2020 Na Liu et al., published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Research Article
  2. MicroRNA-451b participates in coronary heart disease by targeting VEGFA
  3. Case Report
  4. A combination therapy for Kawasaki disease with severe complications: a case report
  5. Vitamin E for prevention of biofilm-caused Healthcare-associated infections
  6. Research Article
  7. Differential diagnosis: retroperitoneal fibrosis and oncological diseases
  8. Optimization of the Convolutional Neural Networks for Automatic Detection of Skin Cancer
  9. NEAT1 promotes LPS-induced inflammatory injury in macrophages by regulating miR-17-5p/TLR4
  10. Plasma matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 as prognostic biomarkers in critically ill patients
  11. Effects of extracorporeal magnetic stimulation in fecal incontinence
  12. Case Report
  13. Mixed germ cell tumor of the endometrium: a case report and literature review
  14. Bowel perforation after ventriculoperitoneal-shunt placement: case report and review of the literature
  15. Research Article
  16. Prognostic value of lncRNA HOTAIR in colorectal cancer : a meta-analysis
  17. Case Report
  18. Treatment of insulinomas by laparoscopic radiofrequency ablation: case reports and literature review
  19. Research Article
  20. The characteristics and nomogram for primary lung papillary adenocarcinoma
  21. Undiagnosed pheochromocytoma presenting as a pancreatic tumor: A case report
  22. Bioinformatics Analysis of the Expression of ATP binding cassette subfamily C member 3 (ABCC3) in Human Glioma
  23. Diagnostic value of recombinant heparin-binding hemagglutinin adhesin protein in spinal tuberculosis
  24. Primary cutaneous DLBCL non-GCB type: challenges of a rare case
  25. LINC00152 knock-down suppresses esophageal cancer by EGFR signaling pathway
  26. Case Report
  27. Life-threatening anaemia in patient with hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)
  28. Research Article
  29. QTc interval predicts disturbed circadian blood pressure variation
  30. Shoulder ultrasound in the diagnosis of the suprascapular neuropathy in athletes
  31. The number of negative lymph nodes is positively associated with survival in esophageal squamous cell carcinoma patients in China
  32. Differentiation of pontine infarction by size
  33. RAF1 expression is correlated with HAF, a parameter of liver computed tomographic perfusion, and may predict the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients
  34. LncRNA ZEB1-AS1 regulates colorectal cancer cells by miR-205/YAP1 axis
  35. Tissue coagulation in laser hemorrhoidoplasty – an experimental study
  36. Classification of pathological types of lung cancer from CT images by deep residual neural networks with transfer learning strategy
  37. Enhanced Recovery after Surgery for Lung Cancer Patients
  38. Case Report
  39. Streptococcus pneumoniae-associated thrombotic microangiopathy in an immunosuppressed adult
  40. Research Article
  41. The characterization of Enterococcus genus: resistance mechanisms and inflammatory bowel disease
  42. Case Report
  43. Inflammatory fibroid polyp: an unusual cause of abdominal pain in the upper gastrointestinal tract A case report
  44. Research Article
  45. microRNA-204-5p participates in atherosclerosis via targeting MMP-9
  46. LncRNA LINC00152 promotes laryngeal cancer progression by sponging miR-613
  47. Can keratin scaffolds be used for creating three-dimensional cell cultures?
  48. miRNA-186 improves sepsis induced renal injury via PTEN/PI3K/AKT/P53 pathway
  49. Case Report
  50. Delayed bowel perforation after routine distal loopogram prior to ileostomy closure
  51. Research Article
  52. Diagnostic accuracy of MALDI-TOF mass spectrometry for the direct identification of clinical pathogens from urine
  53. The R219K polymorphism of the ATP binding cassette subfamily A member 1 gene and susceptibility to ischemic stroke in Chinese population
  54. miR-92 regulates the proliferation, migration, invasion and apoptosis of glioma cells by targeting neogenin
  55. Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
  56. NF2 inhibits proliferation and cancer stemness in breast cancer
  57. Body composition indices and cardiovascular risk in type 2 diabetes. CV biomarkers are not related to body composition
  58. S100A6 promotes proliferation and migration of HepG2 cells via increased ubiquitin-dependent degradation of p53
  59. Review Article
  60. Focus on localized laryngeal amyloidosis: management of five cases
  61. Research Article
  62. NEAT1 aggravates sepsis-induced acute kidney injury by sponging miR-22-3p
  63. Pericentric inversion in chromosome 1 and male infertility
  64. Increased atherogenic index in the general hearing loss population
  65. Prognostic role of SIRT6 in gastrointestinal cancers: a meta-analysis
  66. The complexity of molecular processes in osteoarthritis of the knee joint
  67. Interleukin-6 gene −572 G > C polymorphism and myocardial infarction risk
  68. Case Report
  69. Severe anaphylactic reaction to cisatracurium during anesthesia with cross-reactivity to atracurium
  70. Research Article
  71. Rehabilitation training improves nerve injuries by affecting Notch1 and SYN
  72. Case Report
  73. Myocardial amyloidosis following multiple myeloma in a 38-year-old female patient: A case report
  74. Research Article
  75. Identification of the hub genes RUNX2 and FN1 in gastric cancer
  76. miR-101-3p sensitizes non-small cell lung cancer cells to irradiation
  77. Distinct functions and prognostic values of RORs in gastric cancer
  78. Clinical impact of post-mortem genetic testing in cardiac death and cardiomyopathy
  79. Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
  80. Review Article
  81. The role of osteoprotegerin in the development, progression and management of abdominal aortic aneurysms
  82. Research Article
  83. Identification of key microRNAs of plasma extracellular vesicles and their diagnostic and prognostic significance in melanoma
  84. miR-30a-3p participates in the development of asthma by targeting CCR3
  85. microRNA-491-5p protects against atherosclerosis by targeting matrix metallopeptidase-9
  86. Bladder-embedded ectopic intrauterine device with calculus
  87. Case Report
  88. Mycobacterial identification on homogenised biopsy facilitates the early diagnosis and treatment of laryngeal tuberculosis
  89. Research Article
  90. The will of young minors in the terminal stage of sickness: A case report
  91. Extended perfusion protocol for MS lesion quantification
  92. Identification of four genes associated with cutaneous metastatic melanoma
  93. Case Report
  94. Thalidomide-induced serious RR interval prolongation (longest interval >5.0 s) in multiple myeloma patient with rectal cancer: A case report
  95. Research Article
  96. Voluntary exercise and cardiac remodeling in a myocardial infarction model
  97. Electromyography as an intraoperative test to assess the quality of nerve anastomosis – experimental study on rats
  98. Case Report
  99. CT findings of severe novel coronavirus disease (COVID-19): A case report of Heilongjiang Province, China
  100. Commentary
  101. Directed differentiation into insulin-producing cells using microRNA manipulation
  102. Research Article
  103. Culture-negative infective endocarditis (CNIE): impact on postoperative mortality
  104. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome
  105. Plasma microRNAs in human left ventricular reverse remodelling
  106. Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis
  107. Risk factors for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage
  108. Problems and solutions of personal protective equipment doffing in COVID-19
  109. Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
  110. Review Article
  111. Gastroenterological complications in kidney transplant patients
  112. Research Article
  113. CXCL13 concentration in latent syphilis patients with treatment failure
  114. A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
  115. Case Report
  116. Clinicopathological analysis of composite lymphoma: A two-case report and literature review
  117. Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
  118. Research Article
  119. Inhibition of vitamin D analog eldecalcitol on hepatoma in vitro and in vivo
  120. CCTs as new biomarkers for the prognosis of head and neck squamous cancer
  121. Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet
  122. 72 hour Holter monitoring, 7 day Holter monitoring, and 30 day intermittent patient-activated heart rhythm recording in detecting arrhythmias in cryptogenic stroke patients free from arrhythmia in a screening 24 h Holter
  123. FOXK2 downregulation suppresses EMT in hepatocellular carcinoma
  124. Case Report
  125. Total parenteral nutrition-induced Wernicke’s encephalopathy after oncologic gastrointestinal surgery
  126. Research Article
  127. Clinical prediction for outcomes of patients with acute-on-chronic liver failure associated with HBV infection: A new model establishment
  128. Case Report
  129. Combination of chest CT and clinical features for diagnosis of 2019 novel coronavirus pneumonia
  130. Research Article
  131. Clinical significance and potential mechanisms of miR-223-3p and miR-204-5p in squamous cell carcinoma of head and neck: a study based on TCGA and GEO
  132. Review Article
  133. Hemoperitoneum caused by spontaneous rupture of hepatocellular carcinoma in noncirrhotic liver. A case report and systematic review
  134. Research Article
  135. Voltage-dependent anion channels mediated apoptosis in refractory epilepsy
  136. Prognostic factors in stage I gastric cancer: A retrospective analysis
  137. Circulating irisin is linked to bone mineral density in geriatric Chinese men
  138. Case Report
  139. A family study of congenital dysfibrinogenemia caused by a novel mutation in the FGA gene: A case report
  140. Research Article
  141. CBCT for estimation of the cemento-enamel junction and crestal bone of anterior teeth
  142. Case Report
  143. Successful de-escalation antibiotic therapy using cephamycins for sepsis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia: A sequential 25-case series
  144. Research Article
  145. Influence factors of extra-articular manifestations in rheumatoid arthritis
  146. Assessment of knowledge of use of electronic cigarette and its harmful effects among young adults
  147. Predictive factors of progression to severe COVID-19
  148. Procedural sedation and analgesia for percutaneous trans-hepatic biliary drainage: Randomized clinical trial for comparison of two different concepts
  149. Acute chemoradiotherapy toxicity in cervical cancer patients
  150. IGF-1 regulates the growth of fibroblasts and extracellular matrix deposition in pelvic organ prolapse
  151. NANOG regulates the proliferation of PCSCs via the TGF-β1/SMAD pathway
  152. An immune-relevant signature of nine genes as a prognostic biomarker in patients with gastric carcinoma
  153. Computer-aided diagnosis of skin cancer based on soft computing techniques
  154. MiR-1225-5p acts as tumor suppressor in glioblastoma via targeting FNDC3B
  155. miR-300/FA2H affects gastric cancer cell proliferation and apoptosis
  156. Hybrid treatment of fibroadipose vascular anomaly: A case report
  157. Surgical treatment for common hepatic aneurysm. Original one-step technique
  158. Neuropsychiatric symptoms, quality of life and caregivers’ burden in dementia
  159. Predictor of postoperative dyspnea for Pierre Robin Sequence infants
  160. Long non-coding RNA FOXD2-AS1 promotes cell proliferation, metastasis and EMT in glioma by sponging miR-506-5p
  161. Analysis of expression and prognosis of KLK7 in ovarian cancer
  162. Circular RNA circ_SETD2 represses breast cancer progression via modulating the miR-155-5p/SCUBE2 axis
  163. Glial cell induced neural differentiation of bone marrow stromal cells
  164. Case Report
  165. Moraxella lacunata infection accompanied by acute glomerulonephritis
  166. Research Article
  167. Diagnosis of complication in lung transplantation by TBLB + ROSE + mNGS
  168. Case Report
  169. Endometrial cancer in a renal transplant recipient: A case report
  170. Research Article
  171. Downregulation of lncRNA FGF12-AS2 suppresses the tumorigenesis of NSCLC via sponging miR-188-3p
  172. Case Report
  173. Splenic abscess caused by Streptococcus anginosus bacteremia secondary to urinary tract infection: a case report and literature review
  174. Research Article
  175. Advances in the role of miRNAs in the occurrence and development of osteosarcoma
  176. Rheumatoid arthritis increases the risk of pleural empyema
  177. Effect of miRNA-200b on the proliferation and apoptosis of cervical cancer cells by targeting RhoA
  178. LncRNA NEAT1 promotes gastric cancer progression via miR-1294/AKT1 axis
  179. Key pathways in prostate cancer with SPOP mutation identified by bioinformatic analysis
  180. Comparison of low-molecular-weight heparins in thromboprophylaxis of major orthopaedic surgery – randomized, prospective pilot study
  181. Case Report
  182. A case of SLE with COVID-19 and multiple infections
  183. Research Article
  184. Circular RNA hsa_circ_0007121 regulates proliferation, migration, invasion, and epithelial–mesenchymal transition of trophoblast cells by miR-182-5p/PGF axis in preeclampsia
  185. SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis
  186. Case Report
  187. A case report of cervical pregnancy after in vitro fertilization complicated by tuberculosis and a literature review
  188. Review Article
  189. Serrated lesions of the colon and rectum: Emergent epidemiological data and molecular pathways
  190. Research Article
  191. Biological properties and therapeutic effects of plant-derived nanovesicles
  192. Case Report
  193. Clinical characterization of chromosome 5q21.1–21.3 microduplication: A case report
  194. Research Article
  195. Serum calcium levels correlates with coronary artery disease outcomes
  196. Rapunzel syndrome with cholangitis and pancreatitis – A rare case report
  197. Review Article
  198. A review of current progress in triple-negative breast cancer therapy
  199. Case Report
  200. Peritoneal-cutaneous fistula successfully treated at home: A case report and literature review
  201. Research Article
  202. Trim24 prompts tumor progression via inducing EMT in renal cell carcinoma
  203. Degradation of connexin 50 protein causes waterclefts in human lens
  204. GABRD promotes progression and predicts poor prognosis in colorectal cancer
  205. The lncRNA UBE2R2-AS1 suppresses cervical cancer cell growth in vitro
  206. LncRNA FOXD3-AS1/miR-135a-5p function in nasopharyngeal carcinoma cells
  207. MicroRNA-182-5p relieves murine allergic rhinitis via TLR4/NF-κB pathway
Downloaded on 14.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/med-2020-0118/html
Scroll to top button